Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 15/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.37 |
| ▸ | BRD2 | P25440 | 7/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980664 | 0.91 | ERN1 (0.47) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18249964 | 0.89 | ERN1 (0.46) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18258271 | 0.89 | ERN1 (0.43) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18249961 | 0.89 | ERN1 (0.46) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL18249958 | 0.88 | ERN1 (0.45) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL1903791 | 0.87 | BRD4 (0.51) | BRD4CYP3A4CYP2C9BRD2BRD3 | |
| SCHEMBL1902354 | 0.84 | ERN1 (0.53) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL16619406 | 0.81 | BRD4 (0.44) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL23728841 | 0.81 | BRD4 (0.42) | ERN1BRD4CYP3A4CYP2C9BRD2 | |
| SCHEMBL23728839 | 0.81 | BRD4 (0.42) | ERN1BRD4CYP3A4CYP2C9BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | ERN1 493/4885BRD4 928/4885CYP3A4 4885/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | ERN1 1218/4885BRD4 930/4885CYP3A4 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.